Using inhaled nitroglycerin to improve breathing in late-stage COPD patients
Official title: "The Effect of Inhaled Nitroglycerin on Improving Respiratory Failure in COPD Patients Admitted to Adult Intensive Care Unit"
Run by Beni-Suef University · NCT06785337 · Data updated 2026-11-12
This study is testing if inhaled nitroglycerin can help people with late-stage COPD breathe better and improve their lung function.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Haram, Giza Governorate) |
| Status | Recruiting |
| Started | February 1, 2025 |
| Main results expected | October 1, 2025 |
| Study ends | December 1, 2025 |
| Registry record updated | January 23, 2025 |
| Trial ID | NCT06785337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with COPD exacerbation and evidence of pulmonary hypertension.
✕Probably not a fit
Patients with profound left ventricular failure, pregnant women, or those with hypersensitivity to nitroglycerin may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of nebulized nitroglycerin on respiratory function in patients with late-stage Chronic Obstructive Pulmonary Disease (COPD). The approach focuses on the vasodilation of pulmonary arteries and arterioles, which can alleviate ventilation/perfusion mismatching that exacerbates COPD symptoms. Additionally, the study aims to enhance antibiotic delivery to the alveoli, potentially improving infection control in these patients. It is designed as an interventional study, encompassing both Phase 2 and Phase 3 evaluations.
Why it matters
Potential benefit: If successful, this treatment could significantly improve respiratory function and quality of life for patients with severe COPD.
How similar studies have gone: While the use of inhaled nitroglycerin is a novel approach in this context, similar studies have shown promise in improving respiratory outcomes in other conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient's ≥ 18 years old COPD exacerbation with respiratory failure and Echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure \> 20 mmHg) Exclusion Criteria: * Profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. This may worsen cardiogenic pulmonary edema. * Pregnant female patients * Patient with hypersensitivity to nitroglycerin
Where it's running
-
Haram Hospital
Haram, Giza Governorate, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer
This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.
-
Cognitive load and inhaler technique in COPD
This study tests whether adding a short memory task while using an inhaler makes COPD patients more likely to misuse their inhaler.
-
Balance training after pulmonary rehab for COPD to help steadiness and reduce falls
A COPD-focused balance training program called Sport4Steadiness is being tested to see if people with COPD will accept it and if the study processes work well.
-
Continuous vs High-Intensity Interval Exercise in COPD
This study tests whether continuous versus high-intensity interval exercise affects cerebral oxygenation in people with COPD.
-
Biomarker clues for COPD, IPF, and lung cancer
This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.
-
HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults
This study tests whether HRS-9821 inhalation can be safely taken and help people with moderate to severe COPD, and aims to find a reasonable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.